ATE221886T1 - Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress - Google Patents

Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress

Info

Publication number: ATE221886T1
Authority: AT; Austria
Prior art keywords: antagonists; stress; treatment; corticotropin releasing; crh
Prior art date: 1997-09-02

Application number

AT98942330T

Other languages

English (en)

Inventor

Argyrios G Arvanitis

Paul J Gilligan

James P Beck

Rajagopal Bakthavatchalam

Original Assignee

Bristol Myers Squibb Pharma Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-02

Filing date

1998-09-01

Publication date

2002-08-15

1998-09-01 Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co

2002-08-15 Application granted granted Critical

2002-08-15 Publication of ATE221886T1 publication Critical patent/ATE221886T1/de

Links

102000012289 Corticotropin-Releasing Hormone Human genes 0.000 title abstract 4
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 title abstract 4
239000000055 Corticotropin-Releasing Hormone Substances 0.000 title abstract 4
239000005557 antagonist Substances 0.000 title abstract 2
229940041967 corticotropin-releasing hormone Drugs 0.000 title 2
KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 title 2
RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
150000003230 pyrimidines Chemical class 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
206010048327 Supranuclear palsy Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000000112 colonic effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
230000009610 hypersensitivity Effects 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1
208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

AT98942330T 1997-09-02 1998-09-01 Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress ATE221886T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5743297P	1997-09-02	1997-09-02
PCT/US1998/018080 WO1999011643A1 (en)	1997-09-02	1998-09-01	Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders

Publications (1)

Publication Number	Publication Date
ATE221886T1 true ATE221886T1 (de)	2002-08-15

Family

ID=22010535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98942330T ATE221886T1 (de)	1997-09-02	1998-09-01	Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress

Country Status (11)

Country	Link
US (2)	US6245769B1 (de)
EP (1)	EP1012151B1 (de)
JP (1)	JP2001514260A (de)
CN (1)	CN1278819A (de)
AT (1)	ATE221886T1 (de)
AU (1)	AU9041198A (de)
BR (1)	BR9814458A (de)
CA (1)	CA2303280A1 (de)
DE (1)	DE69807085D1 (de)
IL (1)	IL134748A0 (de)
WO (1)	WO1999011643A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6992188B1 (en)	1995-12-08	2006-01-31	Pfizer, Inc.	Substituted heterocyclic derivatives
EP1218023B8 (de)	1999-10-01	2006-05-03	Johnson & Johnson Consumer Companies, Inc.	Verfahren zur beruhigen von menschen unter verwendung von körperpflegemitteln
WO2002006286A2 (en) *	2000-07-14	2002-01-24	Bristol-Myers Squibb Pharma Company	IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
US20020151527A1 (en) *	2000-12-20	2002-10-17	Benjamin Wiegand	Method for reducing acne or improving skin tone
US6555581B1 (en)	2001-02-15	2003-04-29	Jones Pharma, Inc.	Levothyroxine compositions and methods
US7067148B2 (en)	2001-02-15	2006-06-27	King Pharmaceutical Research & Development, Inc.	Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
BR0208357A (pt)	2001-03-13	2004-06-29	Bristol Myers Squibb Pharma Co	Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto
CA2446980A1 (en) *	2001-05-14	2002-11-21	Argyrios G. Arvanitis	Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
US7462622B2 (en)	2001-06-12	2008-12-09	Glaxo Group Limited	Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists
EP1401411A2 (de) *	2001-06-29	2004-03-31	AB Science	Verwendung von tyrosin kinase hemmern zur behandlung von knochenschwund
JP2005500041A (ja)	2001-06-29	2005-01-06	アブサイエンス	強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
DE60215648T2 (de)	2001-06-29	2007-08-23	Ab Science	Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
JP2004537536A (ja)	2001-06-29	2004-12-16	アブサイエンス	アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
ES2266553T3 (es)	2001-06-29	2007-03-01	Ab Science	Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
AU2002354575A1 (en)	2001-07-12	2003-01-29	Bristol-Myers Squibb Pharma Company	Tetrahydropurinones as corticotropin releasing factor
ATE493988T1 (de) *	2001-07-13	2011-01-15	Btg Internat Ltd Company No 2664412	Pyrimidinderivate enthaltendes medikament
WO2003006015A1 (en)	2001-07-13	2003-01-23	Bristol-Myers Squibb Pharma Company	Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
US7101569B2 (en)	2001-08-14	2006-09-05	Franz G Andrew	Methods of administering levothyroxine pharmaceutical compositions
US20030119831A1 (en)	2001-11-20	2003-06-26	Hartz Richard A.	3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
GB2384563A (en) *	2002-01-29	2003-07-30	Johnson & Johnson Consumer	Method of measuring the stress or relaxation level of a mammal
GB0203045D0 (en) *	2002-02-08	2002-03-27	Johnson & Johnson Consumer	Method of afefecting sleep and sleep-related behaviours
US20040175438A1 (en) *	2003-03-03	2004-09-09	Benjamin Wiegand	Methods for alleviating symptoms associated with menopause using sensory regimen
WO2005028480A2 (en) *	2003-09-03	2005-03-31	Neurogen Corporation	5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
KR20070118068A (ko) *	2004-11-23	2007-12-13	레디 유에스 테라퓨틱스 인코포레이티드	신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물
WO2006086464A2 (en) *	2005-02-10	2006-08-17	Bristol-Myers Squibb Company	Dihydroquinazolinones as 5ht modulators
PT1888548E (pt)	2005-05-26	2012-10-30	Neuron Systems Inc	Derivado de quinolina para o tratamento de doenças da retina
CA2617102A1 (en) *	2005-07-28	2007-02-08	Bristol-Myers Squibb Company	Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) *	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US7851468B2 (en) *	2006-05-15	2010-12-14	Cephalon, Inc.	Substituted pyrazolo[3,4-d]pyrimidines
TW200815349A (en)	2006-06-22	2008-04-01	Astrazeneca Ab	New compounds
TW200902499A (en)	2007-05-15	2009-01-16	Astrazeneca Ab	New compounds
ES2494365T3 (es) *	2008-01-30	2014-09-15	Genentech, Inc.	Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
TW201020244A (en)	2008-11-14	2010-06-01	Astrazeneca Ab	New compounds
US8653098B2 (en)	2008-11-20	2014-02-18	Genentech, Inc.	Pyrazolopyridine PI3K inhibitor compounds and methods of use
PH12012500778A1 (en)	2009-10-30	2012-11-26	Janssen Pharmaceutica Nv	IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2011072141A1 (en)	2009-12-11	2011-06-16	Neuron Systems, Inc.	Compositions and methods for the treatment of macular degeneration
US8329705B2 (en)	2009-12-30	2012-12-11	Arqule, Inc.	Substituted triazolo-pyrazine compounds
AR080754A1 (es)	2010-03-09	2012-05-09	Janssen Pharmaceutica Nv	Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
BR112013033375B1 (pt)	2011-06-27	2022-05-10	Janssen Pharmaceutica N.V	Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
HK1206250A1 (en)	2012-06-26	2016-01-08	Janssen Pharmaceutica Nv	Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en)	2012-07-09	2014-01-16	Janssen Pharmaceutica Nv	Inhibitors of phosphodiesterase 10 enzyme
CA2898631C (en)	2013-01-23	2023-06-13	Aldeyra Therapeutics, Inc.	Toxic aldehyde related diseases and treatment
JP6441356B2 (ja)	2013-09-06	2018-12-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	新規トリアゾロ［４，５−ｄ］ピリミジン誘導体
KR102220260B1 (ko) *	2015-02-18	2021-02-25	버크 인스티튜트 포 리서치 온 에이징	스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
CN118724806A (zh)	2015-08-21	2024-10-01	奥尔德拉医疗公司	氘化化合物和其用途
JP7311162B2 (ja) *	2017-10-10	2023-07-19	アルデイラセラピューティクス，インコーポレイテッド	炎症性障害の処置
CA3089159A1 (en) *	2018-02-06	2019-08-15	Jiangsu Hengrui Medicine Co., Ltd.	Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
WO2020033344A1 (en)	2018-08-06	2020-02-13	Aldeyra Therapeutics, Inc.	Polymorphic compounds and uses thereof
EP3856478A4 (de)	2018-09-25	2022-06-08	Aldeyra Therapeutics, Inc.	Formulierungen zur behandlung von trockenem auge
US11786518B2 (en)	2019-03-26	2023-10-17	Aldeyra Therapeutics, Inc.	Ophthalmic formulations and uses thereof
US12098132B2 (en)	2019-05-02	2024-09-24	Aldeyra Therapeutics, Inc.	Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh)	2019-05-02	2021-12-10	奥尔德拉医疗公司	多晶型化合物和其用途
CN112592346B (zh) *	2019-07-30	2022-04-26	厦门宝太生物科技股份有限公司	一种a2a和/或a2b抑制剂中间体的制备方法
CA3175856A1 (en)	2020-05-13	2021-11-18	Todd Brady	Pharmaceutical formulations and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2643903A1 (fr)	1989-03-03	1990-09-07	Union Pharma Scient Appl	Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
JP2541702B2 (ja) *	1989-10-11	1996-10-09	帝人株式会社	二環性ピリミジン誘導体、その製造方法およびそれを有効成分とする医薬製剤
IT227968Y1 (it)	1992-11-17	1998-01-21	Moris Baroni	Ago per endovene e prelievi di forma estensibile, autoinglobante per evitare punture e contagi a persone e ambienti dopo l'uso
TW370529B (en) *	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
RU2153494C2 (ru) *	1993-10-12	2000-07-27	Дзе Дюпон Мерк Фармасьютикал Компани	1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
AU2265495A (en) *	1994-06-06	1996-01-04	Pfizer Inc.	Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity
TW530047B (en)	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
WO1995034563A1 (en) *	1994-06-16	1995-12-21	Pfizer Inc.	Pyrazolo and pyrrolopyridines
US5563143A (en)	1994-09-21	1996-10-08	Pfizer Inc.	Catechol diether compounds as inhibitors of TNF release
ATE247469T1 (de) *	1995-06-07	2003-09-15	Pfizer	Heterocyclische kondensierte pyrimidin-derivate
DE69628804T2 (de) *	1995-12-08	2003-12-18	Pfizer Inc., New York	Substitutierte heterozyclische Derivate als CRF Antagonisten
ATE217873T1 (de)	1996-01-23	2002-06-15	Novartis Erfind Verwalt Gmbh	Pyrrolopyrimidinen und verfahren zu deren herstellung
TW440563B (en) *	1996-05-23	2001-06-16	Hoffmann La Roche	Aryl pyrimidine derivatives and a pharmaceutical composition thereof

1998
- 1998-09-01 EP EP98942330A patent/EP1012151B1/de not_active Expired - Lifetime
- 1998-09-01 JP JP2000508682A patent/JP2001514260A/ja active Pending
- 1998-09-01 CA CA002303280A patent/CA2303280A1/en not_active Abandoned
- 1998-09-01 US US09/145,231 patent/US6245769B1/en not_active Expired - Lifetime
- 1998-09-01 DE DE69807085T patent/DE69807085D1/de not_active Expired - Lifetime
- 1998-09-01 AT AT98942330T patent/ATE221886T1/de not_active IP Right Cessation
- 1998-09-01 BR BR9814458-8A patent/BR9814458A/pt not_active IP Right Cessation
- 1998-09-01 WO PCT/US1998/018080 patent/WO1999011643A1/en not_active Ceased
- 1998-09-01 AU AU90411/98A patent/AU9041198A/en not_active Abandoned
- 1998-09-01 IL IL13474898A patent/IL134748A0/xx unknown
- 1998-09-01 CN CN98810908A patent/CN1278819A/zh active Pending
2001
- 2001-02-21 US US09/789,673 patent/US6525056B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU9041198A (en)	1999-03-22
US6525056B2 (en)	2003-02-25
WO1999011643A1 (en)	1999-03-11
JP2001514260A (ja)	2001-09-11
CA2303280A1 (en)	1999-03-11
BR9814458A (pt)	2001-10-23
CN1278819A (zh)	2001-01-03
IL134748A0 (en)	2001-04-30
EP1012151A1 (de)	2000-06-28
US6245769B1 (en)	2001-06-12
EP1012151B1 (de)	2002-08-07
US20010025042A1 (en)	2001-09-27
DE69807085D1 (de)	2002-09-12

Legal Events

Date	Code	Title	Description
2003-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE221886T1 (de)	2002-08-15	Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
MY132871A (en)	2007-10-31	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
LV12262A (lv)	1999-04-20	Ar arilaminu kondenseti piridini un pirimidini
BG108425A (en)	2004-12-30	Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor
IL137019A0 (en)	2001-06-14	Azolo triazines and pyrimidines
DK0901374T3 (da)	2004-04-05	Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
AU4270297A (en)	1998-04-02	Pyrazinones and triazinones and their derivatives thereof
ATE177101T1 (de)	1999-03-15	Pyrrolopyrimidine als crf antagonisten
ES2150482T3 (es)	2000-12-01	Pirazolopirimidinas como antagonistas del factor liberador de corticotropina.
DE69416869D1 (de)	1999-04-08	Diazabicyclische neurokinin antagonisten
MY146935A (en)	2012-10-15	4-(2-BUTYLAMINO-2, 7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-yl) PYRAZOLO-[1,5-a]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS
WO2002004453A3 (en)	2002-06-13	PYRROLO[3,4-d]PYRIMIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
MY141511A (en)	2010-05-14	Azolo triazines and pyrimidines
DE69210255D1 (de)	1996-05-30	THIENOPYRAZIN-2,3-DIONE VERWENDBAR BEI DER BEHANDLUNG VON ZNS-STöRUNGEN, UND IHRE HERSTELLUNG.
MY141752A (en)	2010-06-30	Pyrazolotriazines as crf antagonists